drugset / Trial / NCT05747430

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

NCT05747430

Phase 2 Completed 155 enrolled iRenix Medical, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 15 centers in the United States (US).

Timeline

Start
2023-02-22
Primary completion
2025-03-06
Completion
2026-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IRX-101 Unknown
Comparator Providone-Iodine Unknown 5 %

Indications